1
|
Peremiquel-Trillas P, Paytubi S, Pelegrina B, Frias-Gomez J, Carmona Á, Martínez JM, de Francisco J, Benavente Y, Barahona M, Briansó F, Canet-Hermida J, Caño V, Vidal A, Zanca A, Baixeras N, Rodríguez A, Fernández-Gonzalez S, Dueñas N, Càrdenas L, Aytés Á, Bianchi I, Pavón MÀ, Reventós J, Capellà G, Gómez D, Diaz M, Ponce J, Brunet J, Matias-Guiu X, Bosch FX, de Sanjosé S, Alemany L, Pineda M, Marin F, Costas L. An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study. J Pers Med 2022; 12:jpm12071074. [PMID: 35887570 PMCID: PMC9324683 DOI: 10.3390/jpm12071074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/23/2022] [Accepted: 06/27/2022] [Indexed: 11/21/2022] Open
Abstract
Screenwide is a case-control study (2017−2021) including women with incident endometrial and ovarian cancers (EC and OC), BRCA1/2 and MMR pathogenic variant carriers, and age-matched controls from three centers in Spain. Participants completed a personal interview on their sociodemographic factors, occupational exposure, medication, lifestyle, and medical history. We collected biological specimens, including blood samples, self-collected vaginal specimens, cervical pap-brush samples, uterine specimens, and, when available, tumor samples. The planned analyses included evaluation of the potential risk factors for EC/OC; evaluation of molecular biomarkers in minimally invasive samples; evaluation of the cost-effectiveness of molecular tests; and the generation of predictive scores to integrate different epidemiologic, clinical, and molecular factors. Overall, 182 EC, 69 OC, 98 BRCA pathogenic variant carriers, 104 MMR pathogenic variant carriers, and 385 controls were enrolled. The overall participation rate was 85.7%. The pilot study using 61 samples from nine EC cases and four controls showed that genetic variants at the variant allele fraction > 5% found in tumors (n = 61 variants across the nine tumors) were detected in paired endometrial aspirates, clinician-collected cervical samples, and vaginal self-samples with detection rates of 90% (55/61), 79% (48/61), and 72% (44/61) by duplex sequencing, respectively. Among the controls, only one somatic mutation was detected in a cervical sample. We enrolled more than 800 women to evaluate new early detection strategies. The preliminary data suggest that our methodological approach could be useful for the early detection of gynecological cancers.
Collapse
Affiliation(s)
- Paula Peremiquel-Trillas
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Sonia Paytubi
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
| | - Beatriz Pelegrina
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
| | - Jon Frias-Gomez
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Álvaro Carmona
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
| | - José Manuel Martínez
- Department of Gynecology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.M.M.); (M.B.); (S.F.-G.); (J.P.)
| | - Javier de Francisco
- Department of Anesthesiology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.d.F.); (V.C.)
| | - Yolanda Benavente
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Marc Barahona
- Department of Gynecology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.M.M.); (M.B.); (S.F.-G.); (J.P.)
| | - Ferran Briansó
- Department of Genetics, Microbiology and Statistics, Universitat de Barcelona, 08028 Barcelona, Spain;
- Roche Diagnostics, Sant Cugat del Vallès, 08174 Barcelona, Spain
| | - Júlia Canet-Hermida
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
| | - Víctor Caño
- Department of Anesthesiology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.d.F.); (V.C.)
| | - August Vidal
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
- Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain; (A.Z.); (N.B.); (A.R.)
| | - Alba Zanca
- Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain; (A.Z.); (N.B.); (A.R.)
| | - Núria Baixeras
- Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain; (A.Z.); (N.B.); (A.R.)
| | - Axel Rodríguez
- Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain; (A.Z.); (N.B.); (A.R.)
| | - Sergi Fernández-Gonzalez
- Department of Gynecology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.M.M.); (M.B.); (S.F.-G.); (J.P.)
| | - Núria Dueñas
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
| | - Laura Càrdenas
- Department of Gynecology and Obstetrics, Hospital Universitari Dr. Josep Trueta, 17007 Girona, Spain;
| | - Álvaro Aytés
- Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain;
| | - Ilaria Bianchi
- ASSIR Delta, Serveis d’Atenció Primària Delta del Llobregat, Direcció d’Atenció Primària Costa de Ponent, Gerència Territorial Metropolitana Sud, Institut Català de la Salut, 08006 Barcelona, Spain;
| | - Miquel Àngel Pavón
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Jaume Reventós
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, 08017 Barcelona, Spain;
| | - Gabriel Capellà
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
| | - David Gómez
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
| | - Mireia Diaz
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Jordi Ponce
- Department of Gynecology, IDIBELL, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain; (J.M.M.); (M.B.); (S.F.-G.); (J.P.)
| | - Joan Brunet
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
- Medical Oncology Department, Catalan Institute of Oncology, Doctor Josep Trueta Girona University Hospital, 17007 Girona, Spain
| | - Xavier Matias-Guiu
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
- Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain; (A.Z.); (N.B.); (A.R.)
| | - Francesc Xavier Bosch
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
- Universitat Oberta de Catalunya, 08018 Barcelona, Spain
| | - Silvia de Sanjosé
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
- Consultant, National Cancer Institute, Bethesda, MA 20814, USA
| | - Laia Alemany
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
| | - Marta Pineda
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
| | - Fátima Marin
- Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, 08908 Barcelona, Spain; (J.C.-H.); (N.D.); (G.C.); (J.B.); (M.P.); (F.M.)
- Consortium for Biomedical Research in Cancer–CIBERONC, Carlos III Institute of Health, 28029 Madrid, Spain; (A.V.); (X.M.-G.)
| | - Laura Costas
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, l’Hospitalet de Llobregat, 08908 Barcelona, Spain; (P.P.-T.); (S.P.); (B.P.); (J.F.-G.); (Á.C.); (Y.B.); (M.À.P.); (D.G.); (M.D.); (F.X.B.); (L.A.)
- Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain;
- Correspondence:
| |
Collapse
|
2
|
Olivan M, Garcia M, Suárez L, Guiu M, Gros L, Méndez O, Rigau M, Reventós J, Segura MF, de Torres I, Planas J, de la Cruz X, Gomis RR, Morote J, Rodríguez-Barrueco R, Santamaria A. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers (Basel) 2021; 13:6202. [PMID: 34944822 PMCID: PMC8699528 DOI: 10.3390/cancers13246202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 11/29/2021] [Accepted: 12/03/2021] [Indexed: 12/22/2022] Open
Abstract
About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.
Collapse
Affiliation(s)
- Mireia Olivan
- Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), 08907 L’Hospitalet de Llobregat, Spain;
- Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L’Hospitalet de Llobregat, Spain
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
| | - Marta Garcia
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
- Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
| | - Leticia Suárez
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
| | - Marc Guiu
- Cancer Science Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain; (M.G.); (R.R.G.)
| | - Laura Gros
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
| | - Olga Méndez
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
| | - Marina Rigau
- Bellvitge Biomedical Research Institute (IDIBELL), 08908 L’Hospitalet de Llobregat, Spain; (M.R.); (J.R.)
| | - Jaume Reventós
- Bellvitge Biomedical Research Institute (IDIBELL), 08908 L’Hospitalet de Llobregat, Spain; (M.R.); (J.R.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, 08017 Barcelona, Spain
| | - Miguel F. Segura
- Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain;
| | - Inés de Torres
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
- Department of Pathology, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
| | - Jacques Planas
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
- Department of Urology, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
| | - Xavier de la Cruz
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain;
- Group of Clinical and Translational Bioinformatics, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
| | - Roger R. Gomis
- Cancer Science Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain; (M.G.); (R.R.G.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain;
| | - Juan Morote
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
- Department of Urology, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
| | - Ruth Rodríguez-Barrueco
- Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), 08907 L’Hospitalet de Llobregat, Spain;
- Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L’Hospitalet de Llobregat, Spain
| | - Anna Santamaria
- Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; (M.G.); (L.S.); (L.G.); (O.M.); (I.d.T.); (J.P.); (J.M.)
| |
Collapse
|
3
|
Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pavón MÁ, Martínez JM, Climent M, Barahona M, Canet J, Paytubi S, Salinas M, Palomero L, Bianchi I, Reventós J, Capellà G, Diaz M, Vidal A, Piulats JM, Aytés Á, Ponce J, Brunet J, Bosch FX, Matias-Guiu X, Alemany L, de Sanjosé S. New perspectives on screening and early detection of endometrial cancer. Int J Cancer 2019; 145:3194-3206. [PMID: 31199503 DOI: 10.1002/ijc.32514] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 05/27/2019] [Accepted: 05/31/2019] [Indexed: 12/17/2022]
Abstract
Due to the anatomical continuity of the uterine cavity with the cervix, genomic exploitation of material from routine Pap smears and other noninvasive sampling methods represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract. Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addressed in order to accelerate the implementation of novel technologies in a routine screening or clinical setting. We discuss here new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods with a special focus on public health classic screening criteria, highlighting current gaps in knowledge.
Collapse
Affiliation(s)
- Laura Costas
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Jon Frias-Gomez
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Magdalena Guardiola
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Yolanda Benavente
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain
| | - Marta Pineda
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Miquel Á Pavón
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - José M Martínez
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Maite Climent
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Marc Barahona
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Júlia Canet
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Sonia Paytubi
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Mónica Salinas
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Luis Palomero
- Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Ilaria Bianchi
- ASSIR Delta, Direcció d'Atenció Primària Costa de Ponent, SAP Delta del Llobregat, Barcelona, Spain
| | - Jaume Reventós
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Gabriel Capellà
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - Mireia Diaz
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - August Vidal
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.,Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Josep M Piulats
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.,Department of Medical Oncology, IDIBELL, Catalan Institute of Cancer, Hospitalet de Llobregat, Barcelona, Spain
| | - Álvaro Aytés
- Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Jordi Ponce
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Joan Brunet
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.,Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain
| | - Francesc X Bosch
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - Xavier Matias-Guiu
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.,Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Laia Alemany
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain
| | - Silvia de Sanjosé
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,PATH, Seattle, WA
| | | |
Collapse
|
4
|
Costas L, Palomero L, Benavente Y, Guardiola M, Frias-Gomez J, Pavón MÁ, Climent M, Martinez JM, Barahona M, Salinas M, Pineda M, Bianchi I, Reventós J, Capellà G, Diaz M, Vidal A, Piulats JM, Ponce J, Brunet J, Bosch FX, Matias-Guiu X, Alemany L, de Sanjosé S, Aytés Á. Defining a mutational signature for endometrial cancer screening and early detection. Cancer Epidemiol 2019; 61:129-132. [PMID: 31238232 DOI: 10.1016/j.canep.2019.06.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 03/29/2019] [Accepted: 06/11/2019] [Indexed: 11/25/2022]
Abstract
INTRODUCTION The current availability of genomic information represents an opportunity to develop new strategies for early detection of cancer. New molecular tests for endometrial cancer may improve performance and failure rates of histological aspirate-based diagnosis, and provide promising perspectives for a potential screening scenario. However, the selection of relevant biomarkers to develop efficient strategies can be a challenge. MATERIALS AND METHODS We developed an algorithm to identify the largest number of patients with endometrial cancer using the minimum number of somatic mutations based on The Cancer Genome Atlas (TCGA) dataset. RESULTS The algorithm provided the number of subjects with mutations (sensitivity) for a given number of biomarkers included in the signature. For instance, by evaluating the 50 most representative point mutations, up to 81.9% of endometrial cancers can be identified in the TCGA dataset. At gene level, a 92.9% sensitivity can be obtained by interrogating five genes. DISCUSSION We developed a computational method to aid in the selection of relevant genomic biomarkers in endometrial cancer that can be adapted to other cancer types or diseases.
Collapse
Affiliation(s)
- Laura Costas
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
| | - Luis Palomero
- Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Yolanda Benavente
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain
| | - Magdalena Guardiola
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Jon Frias-Gomez
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Miquel Ángel Pavón
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain
| | - Maite Climent
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - José Manuel Martinez
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Marc Barahona
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Mónica Salinas
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Marta Pineda
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Ilaria Bianchi
- ASSIR Delta, Direcció d'Atenció Primària Costa de Ponent, SAP Delta del Llobregat, Gerència Territorial Metropolitana Sud / ICS, Barcelona, Spain
| | - Jaume Reventós
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Gabriel Capellà
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - Mireia Diaz
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - August Vidal
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Maria Piulats
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, IDIBELL, Catalan Institute of Cancer, Hospitalet de Llobregat, Barcelona, Spain
| | - Jordi Ponce
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Joan Brunet
- Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain
| | - Francesc Xavier Bosch
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain
| | - Xavier Matias-Guiu
- Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Laia Alemany
- Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain
| | | | - Álvaro Aytés
- Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
| | | |
Collapse
|
5
|
Rosso M, Lapyckyj L, Besso MJ, Monge M, Reventós J, Canals F, Quevedo Cuenca JO, Matos ML, Vazquez-Levin MH. Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B. Cancer Metab 2019; 7:5. [PMID: 31086659 PMCID: PMC6507066 DOI: 10.1186/s40170-019-0196-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 04/04/2019] [Indexed: 12/17/2022] Open
Abstract
Background Breast cancer (BC) is the most common female cancer and the leading cause of cancer death in women worldwide. Alterations in epithelial cadherin (E-cadherin) expression and functions are associated to BC, but the underlying molecular mechanisms have not been fully elucidated. We have previously reported a novel human E-cadherin splice variant (E-cadherin variant) mRNA. Stable transfectants in MCF-7 human BC cells (MCF7Ecadvar) depicted fibroblast-like cell morphology, E-cadherin wild-type downregulation, and other molecular changes characteristic of the epithelial-to-mesenchymal transition process, reduced cell-cell adhesion, and increased cell migration and invasion. In this study, a two-dimensional differential gel electrophoresis (2D-DIGE) combined with mass spectrometry (MS) protein identification and bioinformatics analyses were done to characterize biological processes and canonical pathways affected by E-cadherin variant expression. Results By 2D-DIGE and MS analysis, 50 proteins were found differentially expressed (≥ Δ1.5) in MCF7Ecadvar compared to control cells. Validation of transcript expression was done in the ten most overexpressed and underexpressed proteins. Bioinformatics analyses revealed that 39 of the 50 proteins identified had been previously associated to BC. Moreover, metabolic processes were the most affected, and glycolysis the canonical pathway most altered. The lactate dehydrogenase B (LDHB) was the highest overexpressed protein, and transcript levels were higher in MCF7Ecadvar than in control cells. In agreement with these findings, MCF7Ecadvar conditioned media had lower glucose and higher lactate levels than control cells. MCF7Ecadvar cell treatment with 5 mM of the glycolytic inhibitor 2-deoxy-glucose led to decreased cell viability, and modulation of LDHB expression in MCF7Ecadvar cells with a specific small interfering RNA resulted in decreased cell proliferation. Finally, a positive association between expression levels of the E-cadherin variant and LDHB transcripts was demonstrated in 21 human breast tumor tissues, and breast tumor samples with higher Ki67 expression showed higher LDHB mRNA levels. Conclusions Results from this investigation contributed to further characterize molecular changes associated to the novel E-cadherin splice variant expression in BC cells. They also revealed an association between expression of the novel variant and changes related to BC progression and aggressiveness, in particular those associated to cell metabolism.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| | - Lara Lapyckyj
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| | - Marta Monge
- 2Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Jaume Reventós
- 3Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Francesc Canals
- 2Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Jorge Oswaldo Quevedo Cuenca
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina
| |
Collapse
|
6
|
Sequeiros T, Rigau M, Chiva C, Montes M, Garcia-Grau I, Garcia M, Diaz S, Celma A, Bijnsdorp I, Campos A, Di Mauro P, Borrós S, Reventós J, Doll A, Paciucci R, Pegtel M, de Torres I, Sabidó E, Morote J, Olivan M. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget 2018; 8:4960-4976. [PMID: 27903962 PMCID: PMC5354884 DOI: 10.18632/oncotarget.13634] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Accepted: 11/07/2016] [Indexed: 01/04/2023] Open
Abstract
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches–such as selected reaction monitoring (SRM)–as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients.
Collapse
Affiliation(s)
- Tamara Sequeiros
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marina Rigau
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Cristina Chiva
- Proteomics Unit, Centre de Regulació Genòmica (CRG), Barcelona, Spain.,Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain
| | - Melania Montes
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Iolanda Garcia-Grau
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marta Garcia
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Sherley Diaz
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Ana Celma
- Department of Urology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Irene Bijnsdorp
- Department of Urology, VU University Medical Center, Amsterdam, The Netherlands
| | - Alex Campos
- Sanford-Burnham Medical Research Institute, La Jolla, California, USA
| | - Primiano Di Mauro
- Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain
| | - Salvador Borrós
- Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain
| | - Jaume Reventós
- Departement of Basic Science, International University of Catalonia, Barcelona, Spain.,IDIBELL-Bellvitge Biomedical Research Institute, Barcelona, Spain
| | - Andreas Doll
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Rosanna Paciucci
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Michiel Pegtel
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
| | - Inés de Torres
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.,Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Eduard Sabidó
- Proteomics Unit, Centre de Regulació Genòmica (CRG), Barcelona, Spain.,Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain
| | - Juan Morote
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.,Department of Urology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Mireia Olivan
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
7
|
Morote J, Trilla E, Esquena S, Abascal JM, Segura RM, Catalan R, Encabo G, Reventós J. Analysis of Bone Alkaline Phosphatase as a Marker for the Diagnosis of Osteoporosis in Men under Androgen Ablation. Int J Biol Markers 2018; 18:290-4. [PMID: 14756545 DOI: 10.1177/172460080301800407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The objective of this study was to evaluate the usefulness of serum determination of bone alkaline phosphatase (BAP) in the diagnosis of osteoporosis in men with prostate cancer under androgen ablation. Serum levels of BAP and bone mineral density (BMD) were assessed in 110 patients with non-metastatic, treated prostate cancer. Fifty-eight patients were under androgen deprivation during a period between two and 96 months and 52 had been submitted only to radical prostatectomy. Mean serum BAP was 11.8 ng/mL in patients with normal BMD, 16.7 ng/mL in patients with osteopenia (p. 0.058), and 19.3 ng/mL in patients with osteoporosis (p=0.044). The correlation between serum BAP and BMD was significant (p. 0.006) but with an index of only 0.26. Receiver operating characteristic analysis for the diagnosis of osteoporosis showed an area under the curve of 0.608. None of the cutoff points that provided specificities of 75%, 90% and 95% gave significant distributions. The positive and negative predictive values as well as the odds ratios were not of any clinical usefulness. We conclude that serum BAP should not be considered a good marker for the diagnosis of osteoporosis in men with prostate cancer. Therefore, BAP serum determination cannot replace bone densitometry as a diagnostic tool.
Collapse
Affiliation(s)
- J Morote
- Department of Urology, Autonoma University of Barcelona, School of Medicine, Vail d'Hebron Hospital, Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Morote J, Esquena S, Abascal J, Trilla E, Cecchini L, Raventós C, Catalín R, Reventós J. Behavior of free Testosterone in Patients with Prostate Cancer on Androgen Deprivation Therapy. Int J Biol Markers 2018. [DOI: 10.1177/172460080502000206] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives Determination of free testosterone (FT) serum level is an efficient method to evaluate bioavailable testosterone. We analyzed the behavior of serum FT in patients with prostate cancer receiving androgen deprivation therapy (ADT) and correlated FT with total testosterone (TT). We also analyzed the efficiency of both isoforms in the evaluation of the ADT. Methods Serum levels of TT and FT were determined in 191 patients with prostate cancer in a cross-sectional study. A subset of 56 patients submitted only to radical prostatectomy served as control group. The remaining 135 patients with advanced prostate cancer on three-month LHRH agonist treatment comprised the study group. The median age of the population was 73 years (range, 53–86 years) and the median time on ADT was 42 months (6–198). Results A significant correlation and linear regression between TT and FT was observed (r2 0.948). The efficiency of TT and FT to discriminate patients with and without ADT was similar (AUC: 0.993 and 0.995, respectively, p>0.05). A castration level of serum FT established at 1.7 pg/mL had a sensitivity of 85.9% and a specificity of 100%, which are similar to the sensitivity and specificity of 50 ng/dL of TT. All patients without ADT had levels of serum TT and FT above the castration level. In 19 of the 135 (14.1%) patients on ADT serum TT was above 50 ng/dL. In 12 of these 19 patients (63.2%) serum FT was below 1.7 pg/mL while in seven patients (5.2%) FT was also above the castration level. Conclusions The castration level of FT was established at 1.7 pg/mL. Serum TT and TF correlated very well; however, they seemed to provide complementary information in the evaluation of ADT efficiency. 14.1% of the patients on ADT failed to reach the castration level of serum TT; determination of serum FT in these patients would reduce this rate to 5.2%.
Collapse
Affiliation(s)
- J. Morote
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - S. Esquena
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - J.M. Abascal
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - E. Trilla
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - L. Cecchini
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - C.X. Raventós
- Department of Urology, Vall d'Hebron University Hospital, Barcelona - Spain
| | - R. Catalín
- Department of Biochemistry, Vall d'Hebron University Hospital, Barcelona - Spain
| | - J. Reventós
- Basic Research Unit, Vall d'Hebron University Hospital, Barcelona - Spain
| |
Collapse
|
9
|
Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Orsola A, Planas J, Catalán R, Reventós J. Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer. Int J Biol Markers 2018; 20:209-16. [PMID: 16398402 DOI: 10.1177/172460080502000403] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. In a group of 185 metastatic prostate cancer patients who received androgen deprivation therapy serum PSA was determined every three months until AIP occurred. Multiple regression analysis was performed to define independent clinical and PSA-related predictors of AIP. AIP was assumed to be present after two consecutive increases in serum PSA after the PSA nadir. Independent predictors of the duration of AIP-free survival (less than 12 months versus more than 12 months) were the extent of bone involvement (six or fewer hot spots versus more than six) with an odds ratio (O.R.) of 3.95, Gleason score (7 or less versus more than 7) with an O.R. of 3.47, and PSA nadir (2 μg/L or less versus more than 2 μg/L) with an O.R. of 14.63. AIP was independently predicted by the extent of bone involvement with an O.R. of 1.72, Gleason score with an O.R. of 1.74, PSA nadir with an O.R. of 3.22, and time to reach the PSA nadir (9 months or less versus more than 9 months) with an O.R. of 2.84. When patients were stratified according to these predictors, those with three good prognostic factors had a median AIP-free survival of 58 months while those with two, one or no good prognostic factors had a median AIP-free survival of 19 months, 12 months and 7 months, respectively. We conclude that the PSA nadir seems to be a good predictor of AIP in patients with metastatic prostate cancer after androgen deprivation therapy. Time to PSA nadir, extent of bone involvement and Gleason score are also independent predictors. The combination of these prognostic factors allows to stratify metastatic prostate cancer patients for the prediction of AIP.
Collapse
Affiliation(s)
- J Morote
- Department of Urology, Vail d'Hebron University Hospital, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017. [PMID: 28934230 DOI: 10.1371/journal.pone.0184439] [] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| |
Collapse
|
11
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017. [PMID: 28934230 DOI: 10.1371/journal.pone.0184439]+[] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| |
Collapse
|
12
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017; 12:e0184439. [PMID: 28934230 PMCID: PMC5608212 DOI: 10.1371/journal.pone.0184439] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2017] [Accepted: 08/23/2017] [Indexed: 12/21/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
- * E-mail: ,
| |
Collapse
|
13
|
García-Sanz P, Triviño JC, Mota A, Pérez López M, Colás E, Rojo-Sebastián A, García Á, Gatius S, Ruiz M, Prat J, López-López R, Abal M, Gil-Moreno A, Reventós J, Matias-Guiu X, Moreno-Bueno G. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. Int J Cancer 2017; 140:1551-1563. [PMID: 27997699 DOI: 10.1002/ijc.30573] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 11/10/2016] [Accepted: 12/02/2016] [Indexed: 12/29/2022]
Abstract
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non-endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low-grade, non-ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE-positive endometrioid endometrial carcinomas (EECs). We performed exome-sequencing of 11 EECs with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodelling-related genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA-repair-related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency toward co-occurrence (RAD50-KMT2D and RAD50-SETD1B). All these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches.
Collapse
Affiliation(s)
- Pablo García-Sanz
- MD Anderson International Foundation, Madrid, Spain.,Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | | | - Alba Mota
- MD Anderson International Foundation, Madrid, Spain.,Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - María Pérez López
- MD Anderson International Foundation, Madrid, Spain.,Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - Eva Colás
- Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Arnau de Vilanova University Hospital, University of Lleida, IRBLleida, Lleida, Spain
| | | | - Ángel García
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Sonia Gatius
- Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Arnau de Vilanova University Hospital, University of Lleida, IRBLleida, Lleida, Spain
| | - María Ruiz
- Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Arnau de Vilanova University Hospital, University of Lleida, IRBLleida, Lleida, Spain
| | - Jaime Prat
- Pathology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain
| | - Rafael López-López
- Translational Medical Oncology, Health Research Institute of Santiago (IDIS), SERGAS, Santiago de Compostela, Spain
| | - Miguel Abal
- Translational Medical Oncology, Health Research Institute of Santiago (IDIS), SERGAS, Santiago de Compostela, Spain
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jaume Reventós
- Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Barcelona, Spain.,Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Arnau de Vilanova University Hospital, University of Lleida, IRBLleida, Lleida, Spain
| | - Gema Moreno-Bueno
- MD Anderson International Foundation, Madrid, Spain.,Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| |
Collapse
|
14
|
Eritja N, Chen BJ, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, Encinas M, Ribera J, Reventós J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navàs D. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017; 13:608-624. [PMID: 28055301 PMCID: PMC5361596 DOI: 10.1080/15548627.2016.1271512] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma. Unfortunately, sorafenib showed very modest effects in a multi-institutional phase II trial in advanced uterine carcinoma patients. Here, by leveraging RNA-sequencing data from the Cancer Cell Line Encyclopedia and cell survival studies from compound-based high-throughput screenings we have identified the lysosomal pathway as a potential compartment involved in the resistance to sorafenib. By performing additional functional biology studies we have demonstrated that this resistance could be related to macroautophagy/autophagy. Specifically, our results indicate that sorafenib triggers a mechanistic MAPK/JNK-dependent early protective autophagic response in EC cells, providing an adaptive response to therapeutic stress. By generating in vivo subcutaneous EC cell line tumors, lung metastatic assays and primary EC orthoxenografts experiments, we demonstrate that targeting autophagy enhances sorafenib cytotoxicity and suppresses tumor growth and pulmonary metastasis progression. In conclusion, sorafenib induces the activation of a protective autophagic response in EC cells. These results provide insights into the unopposed resistance of advanced EC to sorafenib and highlight a new strategy for therapeutic intervention in recurrent EC.
Collapse
Affiliation(s)
- Núria Eritja
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | | | | | - Maria Santacana
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | - Sònia Gatius
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | - August Vidal
- e Department of Pathology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Maria Dolores Martí
- f Department of Gynecology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Jordi Ponce
- f Department of Gynecology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Laura Bergadà
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | - Andree Yeramian
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | - Mario Encinas
- g Department of Experimental Medicine , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.8 , Lleida , Spain
| | - Joan Ribera
- g Department of Experimental Medicine , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.8 , Lleida , Spain
| | - Jaume Reventós
- e Department of Pathology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain.,f Department of Gynecology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Jeff Boyd
- h Department of Human and Molecular Genetics , Herbert Wertheim College of Medicine, Florida International University , Miami , FL , USA
| | - Alberto Villanueva
- i Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE) , Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Xavier Matias-Guiu
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain.,e Department of Pathology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain.,f Department of Gynecology , University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Catalonia , Spain
| | - Xavier Dolcet
- a Department of Basic Sciences , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4 , Lleida , Spain.,b Department of Pathology , Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova , Lleida , Spain
| | - David Llobet-Navàs
- d Institute of Genetic Medicine, Newcastle University , Newcastle-Upon-Tyne , UK
| |
Collapse
|
15
|
Devis L, Masiá N, Martínez E, Brochard-Wyart F, Gil-Moreno A, Dufour S, Santamaria A, Alameda F, Reventós J, Colás E. The dual role of ALCAM in endometrial cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61363-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Campoy I, Lanau L, Altadill T, Sequeiros T, Cabrera S, Cubo-Abert M, Pérez-Benavente A, Garcia A, Borrós S, Santamaria A, Ponce J, Matias-Guiu X, Reventós J, Gil-Moreno A, Rigau M, Colas E. Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols. J Transl Med 2016; 14:180. [PMID: 27317346 PMCID: PMC4912787 DOI: 10.1186/s12967-016-0935-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Accepted: 06/02/2016] [Indexed: 01/05/2023] Open
Abstract
Background Uterine aspirates are used in the diagnostic process of endometrial disorders, yet further applications could emerge if its complex milieu was simplified. Exosome-like vesicles isolated from uterine aspirates could become an attractive source of biomarkers, but there is a need to standardize isolation protocols. The objective of the study was to determine whether exosome-like vesicles exist in the fluid fraction of uterine aspirates and to compare protocols for their isolation, characterization, and analysis. Methods We collected uterine aspirates from 39 pre-menopausal women suffering from benign gynecological diseases. The fluid fraction of 27 of those aspirates were pooled and split into equal volumes to evaluate three differential centrifugation-based procedures: (1) a standard protocol, (2) a filtration protocol, and (3) a sucrose cushion protocol. Characterization of isolated vesicles was assessed by electron microscopy, nanoparticle tracking analysis and immunoblot. Specifically for RNA material, we evaluate the effect of sonication and RNase A treatment at different steps of the protocol. We finally confirmed the efficiency of the selected methods in non-pooled samples. Results All protocols were useful to isolate exosome-like vesicles. However, the Standard procedure was the best performing protocol to isolate exosome-like vesicles from uterine aspirates: nanoparticle tracking analysis revealed a higher concentration of vesicles with a mode of 135 ± 5 nm, and immunoblot showed a higher expression of exosome-related markers (CD9, CD63, and CD81) thus verifying an enrichment in this type of vesicles. RNA contained in exosome-like vesicles was successfully extracted with no sonication treatment and exogenous nucleic acids digestion with RNaseA, allowing the analysis of the specific inner cargo by Real-Time qPCR. Conclusion We confirmed the existence of exosome-like vesicles in the fluid fraction of uterine aspirates. They were successfully isolated by differential centrifugation giving sufficient proteomic and transcriptomic material for further analyses. The Standard protocol was the best performing procedure since the other two tested protocols did not ameliorate neither yield nor purity of exosome-like vesicles. This study contributes to establishing the basis for future comparative studies to foster the field of biomarker research in gynecology. Electronic supplementary material The online version of this article (doi:10.1186/s12967-016-0935-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Irene Campoy
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Lucia Lanau
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Tatiana Altadill
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Tamara Sequeiros
- Biomedical Research Group in Urology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Silvia Cabrera
- Department of Gynecology, Vall Hebron University Hospital, Barcelona, Spain
| | | | | | - Angel Garcia
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Salvador Borrós
- Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià, Universitat Ramon Llull, Barcelona, Spain
| | - Anna Santamaria
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jordi Ponce
- Department of Gynecology, Bellvitge Teaching Hospital, Barcelona, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics/Oncologic Pathology Group, University Hospital Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain
| | - Jaume Reventós
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Basic Sciences Department, International University of Catalonia, Barcelona, Spain
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Gynecology, Vall Hebron University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Eva Colas
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. .,Department of Pathology and Molecular Genetics/Oncologic Pathology Group, University Hospital Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain.
| |
Collapse
|
17
|
Rosso M, Majem B, Devis L, Lapyckyj L, Llauradó M, Lanau L, Abascal MF, Matos ML, Besso MJ, Castellví J, Sanchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Reventós J, Rigau M, Vazquez-Levin M. Abstract 4093: Cadherin “switch” and ovarian cancer: Studies using in vitro models and patient samples. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ovarian cancer (OC) is the 5th leading cause of cancer deaths in women worldwide due to late symptoms and its diagnosis at advanced stages. Epithelial to mesenchymal transition (EMT) is an important step in cancer invasion/metastasis and downregulation of Epithelial cadherin (Ecad) is a critical feature of this process. Ecad expression was evaluated in 100 OC tissue sections, finding a decreased Ecad signal along tumor stage, with highest expression in stage I/II (no invasive) and lowest in stage IV (invasive) tumors. These results are in agreement with previous reports showing reduced Ecad expression in correlation with poor prognosis in OC patients. In some cases, Ecad downregulation is accompanied by increased Neural cadherin (Ncad) expression and acquisition of migratory/mesenchymal features. Although this cadherin “switch” has been reported in OC, current data is inconclusive. Expression of Ecad, Ncad and other EMT markers was studied in 4 OC cell lines and according to their levels they were classified as epithelial (OV90), intermediate epithelial (OAW42), intermediate mesenchymal (SKOV3) and mesenchymal (TOV112) cells. The mechanisms underlying regulation of Ecad levels were evaluated by assessing expression of its transcriptional repressors Twist, Snail, Slug, Zeb1. Migration properties were also studied, being significantly higher in TOV112 and SKOV3 cells. It has been proposed that OC cells shed from the primary tumor aggregate as spheroids in the ascites, maintain cellular contacts and survive in suspension. To mimic ovarian tumor cell dissemination through the ascites and to evaluate the role of the cadherin “switch” in this process, cell lines were grown under anchorage-independent conditions. The aggregates number/area was analyzed, being the SKOV3 spheroids the most compacted. When Ecad, Ncad and EMT markers expression was determined similar findings were obtained when spheroids were compared to monolayers, suggesting an intrinsic cell gene expression pattern rather than a response to a cell culture growth condition. The OC spheroids survival was assessed by estimating cell death, finding a positive correlation between high Ncad levels and cell aggregates with low% cell death. Spheroid adhesion/dissemination in extracellular matrices and 3D-spheroid matrigel assays were done to assess invasion at a secondary site. Spheroids from cells with mesenchymal/intermediate mesenchymal phenotypes adhered to extracellular matrices and invaded more than cells with intermediate epithelial/epithelial phenotypes. Finally, Ecad/Ncad expression studies done on primary cultures derived from tumor and ascitic cells from patients with OC revealed a diminished Ecad and a higher Ncad expression in ascitic cells compared to primary tumor cells. Altogether, the data here presented reveals an association between OC cell aggressiveness and a mesenchymal-like molecular profile; and it depends on the expression of Ecad and Ncad markers.
Citation Format: Marina Rosso, Blanca Majem, Laura Devis, Lara Lapyckyj, Marta Llauradó, Lucía Lanau, María Florencia Abascal, María Laura Matos, María José Besso, Josep Castellví, Jose Luís Sanchez-Iglesias, Asunción Pérez-Benavente, Antonio Gil-Moreno, Jaume Reventós, Marina Rigau, Mónica Vazquez-Levin. Cadherin “switch” and ovarian cancer: Studies using in vitro models and patient samples. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4093. doi:10.1158/1538-7445.AM2015-4093
Collapse
Affiliation(s)
- Marina Rosso
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Blanca Majem
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Laura Devis
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Marta Llauradó
- 3Faculty of Medicine, University of British Columbia, Vancouver, Canada
| | - Lucía Lanau
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - María Laura Matos
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - María José Besso
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Josep Castellví
- 4Department of Pathology, Vall Hebron University Hospital, Barcelona, Spain
| | | | | | - Antonio Gil-Moreno
- 5Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Marina Rigau
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Mónica Vazquez-Levin
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| |
Collapse
|
18
|
Sequeiros T, Bastarós JM, Sánchez M, Rigau M, Montes M, Placer J, Planas J, de Torres I, Reventós J, Pegtel DM, Doll A, Morote J, Olivan M. Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Prostate 2015; 75:1102-13. [PMID: 25845829 DOI: 10.1002/pros.22995] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 03/04/2015] [Indexed: 12/11/2022]
Abstract
INTRODUCTION High-grade prostatic intraepithelial neoplasia (HGPIN) is a recognized precursor stage of PCa. Men who present HGPIN in a first prostate biopsy face years of active surveillance including repeat biopsies. This study aimed to identify non-invasive prognostic biomarkers that differentiate early on between indolent HGPIN cases and those that will transform into actual PCa. METHODS We measured the expression of 21 candidate mRNA biomarkers using quantitative PCR in urine sediment samples from a cohort of 90 patients with initial diagnosis of HGPIN and a posterior follow up of at least two years. Uni- and multivariate statistical analyses were applied to analyze the candidate biomarkers and multiplex models using combinations of these biomarkers. RESULTS PSMA, PCA3, PSGR, GOLM, KLK3, CDH1, and SPINK1 behaved as predictors for PCa presence in repeat biopsies. Multiplex models outperformed (AUC = 0.81-0.86) the predictive power of single genes, including the FDA-approved PCA3 (AUC = 0.70). With a fixed sensitivity of 95%, the specificity of our multiplex models was of 41-58%, compared to the 30% of PCA3. The PPV of our models (30-38%) was also higher than the PPV of PCA3 (27%), suggesting that benign cases could be more accurately identified. Applying statistical models, we estimated that 33% to 47% of repeat biopsies could be prevented with a multiplex PCR model, representing an easy applicable and significant advantage over the current gold standard in urine sediment. DISCUSSION Using multiplex RTqPCR-based models in urine sediment it is possible to improve the current diagnostic method of choice (PCA3) to differentiate between benign HGPIN and PCa cases.
Collapse
Affiliation(s)
- Tamara Sequeiros
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Juan M Bastarós
- Department of Urology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Milagros Sánchez
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marina Rigau
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Melania Montes
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - José Placer
- Department of Urology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Jaques Planas
- Department of Urology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Inés de Torres
- Department of Pathology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Jaume Reventós
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
- IDIBELL- Bellvitge Biomedical Research Institute, Barcelona, Spain
| | - D Michiel Pegtel
- Department of Pathology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Andreas Doll
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Juan Morote
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- Department of Urology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Mireia Olivan
- Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
19
|
Yáñez-Mó M, Siljander PRM, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NHH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen ENM, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MHM, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015; 4:27066. [PMID: 25979354 PMCID: PMC4433489 DOI: 10.3402/jev.v4.27066] [Citation(s) in RCA: 3449] [Impact Index Per Article: 383.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/24/2015] [Accepted: 03/10/2015] [Indexed: 12/11/2022] Open
Abstract
In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system.
Collapse
Affiliation(s)
- María Yáñez-Mó
- Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain
- Departamento de Biología Molecular, UAM, Madrid, Spain; ;
| | - Pia R-M Siljander
- Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland;
| | - Zoraida Andreu
- Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain
- Departamento de Biología Molecular, UAM, Madrid, Spain
| | - Apolonija Bedina Zavec
- Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia
| | - Francesc E Borràs
- IVECAT Group - "Germans Trias i Pujol" Research Institute, Badalona, Spain
- Nephrology Service - "Germans Trias i Pujol" University Hospital, Badalona, Spain
| | - Edit I Buzas
- Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary
| | - Krisztina Buzas
- Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary
- Faculty of Dentistry, University of Szeged, Szeged, Hungary
| | - Enriqueta Casal
- Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain
| | - Francesco Cappello
- Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy
- Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
| | - Joana Carvalho
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
| | - Eva Colás
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous University of Barcelona, Barcelona, Spain
| | - Anabela Cordeiro-da Silva
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
- Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal
| | - Stefano Fais
- Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy
| | - Juan M Falcon-Perez
- Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | | | - Bernd Giebel
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Mario Gimona
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria
- Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria
| | - Michael Graner
- Department of Neurosurgery, University of Colorado Denver, CO, USA
| | - Ihsan Gursel
- Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey
| | - Mayda Gursel
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
| | - Niels H H Heegaard
- Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
- Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
| | - An Hendrix
- Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium
| | - Peter Kierulf
- Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | | | - Maja Kosanovic
- Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia
| | - Veronika Kralj-Iglic
- Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | - Eva-Maria Krämer-Albers
- Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany
| | - Saara Laitinen
- Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland
| | - Cecilia Lässer
- Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Thomas Lener
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria
- Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria
| | - Erzsébet Ligeti
- Department of Physiology, Semmelweis University, Budapest, Hungary
| | - Aija Linē
- Latvian Biomedical Research and Study Centre, Riga, Latvia
| | - Georg Lipps
- Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Alicia Llorente
- Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway
| | - Jan Lötvall
- Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Mateja Manček-Keber
- National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia
- EN→FIST Centre of Excellence, Ljubljana, Slovenia
| | - Antonio Marcilla
- Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain
| | - Maria Mittelbrunn
- Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
| | - Irina Nazarenko
- Institute for Environmental Health Sciences and Hospital Infection ControlMedical Center - University of Freiburg, Freiburg im Breisgau, Germany
| | - Esther N M Nolte-'t Hoen
- Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Tuula A Nyman
- Institute of Biotechnology, (Viikinkaari 1), University of Helsinki, Helsinki, Finland
| | - Lorraine O'Driscoll
- School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous University of Barcelona, Barcelona, Spain
| | - Carla Oliveira
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
- Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal
| | - Éva Pállinger
- Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary
| | - Hernando A Del Portillo
- ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
- Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous University of Barcelona, Barcelona, Spain
- Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, and Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain
| | - Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous University of Barcelona, Barcelona, Spain
| | - Eva Rohde
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria
- Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria
| | - Marei Sammar
- Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel
| | - Francisco Sánchez-Madrid
- Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain
| | - N Santarém
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
| | - Katharina Schallmoser
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria
- Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria
| | | | - Willem Stoorvogel
- Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Roman Stukelj
- Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | - Susanne G Van der Grein
- Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - M Helena Vasconcelos
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
- Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal
| | - Marca H M Wauben
- Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Olivier De Wever
- Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium
| |
Collapse
|
20
|
Pedrola N, Devis L, Llauradó M, Campoy I, Martinez-Garcia E, Garcia M, Muinelo-Romay L, Alonso-Alconada L, Abal M, Alameda F, Mancebo G, Carreras R, Castellví J, Cabrera S, Gil-Moreno A, Matias-Guiu X, Iovanna JL, Colas E, Reventós J, Ruiz A. Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clin Exp Metastasis 2015; 32:467-78. [PMID: 25924802 DOI: 10.1007/s10585-015-9720-7] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Accepted: 04/20/2015] [Indexed: 11/28/2022]
Abstract
Endometrial cancer is the most frequent malignancy of the female genital tract in western countries. Our group has previously characterized the upregulation of the transcription factor ETV5 in endometrial cancer with a specific and significant increase in those tumor stages associated with myometrial invasion. We have shown that ETV5 overexpression in Hec1A endometrial cancer cells induces epithelial to mesenchymal transition resulting in the acquisition of migratory and invasive capabilities. In the present work, we have identified Nidogen 1 (NID1) and Nuclear Protein 1 (NUPR1) as direct transcriptional targets of ETV5 in endometrial cancer cells. Inhibition of NID1 and NUPR1 in ETV5 overexpressing cells reduced cell migration and invasion in vitro and reduced tumor growth and dissemination in an orthotopic endometrial cancer model. Importantly, we confirmed a significant increase of NUPR1 and NID1 protein expression in the invasion front of the tumor compared to their paired superficial zone, concomitant to ETV5 overexpression. Altogether, we conclude that NID1 and NUPR1 are novel targets of ETV5 and are actively cooperating with ETV5 at the invasion front of the tumor in the acquisition of an invasive phenotype to jointly drive endometrial cancer invasion.
Collapse
Affiliation(s)
- Núria Pedrola
- Biomedical Research Group in Ginaecology, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, 08035, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Majem B, Rigau M, Reventós J, Wong DT. Non-coding RNAs in saliva: emerging biomarkers for molecular diagnostics. Int J Mol Sci 2015; 16:8676-98. [PMID: 25898412 PMCID: PMC4425103 DOI: 10.3390/ijms16048676] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 04/02/2015] [Accepted: 04/08/2015] [Indexed: 01/05/2023] Open
Abstract
Saliva is a complex body fluid that comprises secretions from the major and minor salivary glands, which are extensively supplied by blood. Therefore, molecules such as proteins, DNA, RNA, etc., present in plasma could be also present in saliva. Many studies have reported that saliva body fluid can be useful for discriminating several oral diseases, but also systemic diseases including cancer. Most of these studies revealed messenger RNA (mRNA) and proteomic biomarker signatures rather than specific non-coding RNA (ncRNA) profiles. NcRNAs are emerging as new regulators of diverse biological functions, playing an important role in oncogenesis and tumor progression. Indeed, the small size of these molecules makes them very stable in different body fluids and not as susceptible as mRNAs to degradation by ribonucleases (RNases). Therefore, the development of a non-invasive salivary test, based on ncRNAs profiles, could have a significant applicability to clinical practice, not only by reducing the cost of the health system, but also by benefitting the patient. Here, we summarize the current status and clinical implications of the ncRNAs present in human saliva as a source of biological information.
Collapse
Affiliation(s)
- Blanca Majem
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
| | - Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
- IDIBELL-Bellvitge Biomedical Research Institute & Universitat Internacional de Catalunya, 08908 Barcelona, Spain.
| | - David T Wong
- Center for Oral/Head & Neck Oncology Research, University of California, Los Angeles, CA 90095, USA.
| |
Collapse
|
22
|
Bastarós JM, Sequeiros T, Placer J, Planas J, Regis L, Sánchez M, Rigau M, Montes M, de Torres I, Reventós J, Doll A, Morote J. MP6-01 URINARY BIOMARKERS FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (HGPIN). J Urol 2015. [DOI: 10.1016/j.juro.2015.02.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Santacana M, Maiques O, Valls J, Gatius S, Abó AI, López-García MÁ, Mota A, Reventós J, Moreno-Bueno G, Palacios J, Bartosch C, Dolcet X, Matias-Guiu X. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol 2014; 45:2394-403. [DOI: 10.1016/j.humpath.2014.06.031] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 06/25/2014] [Accepted: 06/28/2014] [Indexed: 01/28/2023]
|
24
|
Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventós J, Doll A. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci 2014; 15:13615-23. [PMID: 25101846 PMCID: PMC4159814 DOI: 10.3390/ijms150813615] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 07/11/2014] [Accepted: 07/11/2014] [Indexed: 12/23/2022] Open
Abstract
The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p < 0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p < 0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p = 0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p = 0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p = 0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p < 0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p < 0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p = 0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56–2.24) and HGPCa risk, OR 0.31 (95% CI 0.23–0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol.
Collapse
Affiliation(s)
- Juan Morote
- Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Anna Celma
- Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Jacques Planas
- Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - José Placer
- Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Inés de Torres
- Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Juan Carles
- Department of Medical Oncology, Vall d'Hebron University and Hospital Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Andreas Doll
- Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain.
| |
Collapse
|
25
|
Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M. MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol 2014; 390:73-84. [PMID: 24747602 DOI: 10.1016/j.mce.2014.03.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 02/09/2014] [Accepted: 03/25/2014] [Indexed: 01/18/2023]
Abstract
Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment. Mechanisms of chemoresistance in cancer cells may be associated with mutational events and/or alterations of gene expression through epigenetic events. Although focusing on known genes has already yielded new information, previously unknown non-coding RNAs, such as microRNAs (miRNAs), also lead insight into the biology of chemoresistance. In this review we summarize the current evidence examining the role of miRNAs as biomarkers of response and survival to therapy in OC. Beside their clinical implications, we also discuss important differences between studies that may have limited their use as clinical biomarkers and suggest new approaches.
Collapse
Affiliation(s)
- Marta Llauradó
- Faculty of Medicine, University of British Columbia, Vancouver, Canada; Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Blanca Majem
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Tatiana Altadill
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Lucia Lanau
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Josep Castellví
- Department of Pathology, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Silvia Cabrera
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Javier De la Torre
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Berta Díaz-Feijoo
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Eva Colás
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Andreas Doll
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Francesc Alameda
- Department of Pathology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain
| | - Gema Moreno-Bueno
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, 28029, Madrid, Spain & Fundación MD Anderson Internacional, 28033 Madrid, Spain
| | - Mark S Carey
- Division of Gynecologic Oncology, University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada
| | - Josep Maria Del Campo
- Division of Gynecology and Head and Neck, Department of Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Antonio Gil-Moreno
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain; Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain; Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain; IDIBELL- Bellvitge Biomedical Research Institute, Barcelona, Spain.
| | - Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| |
Collapse
|
26
|
Morote J, Celma A, Planas J, Placer J, Konstantinidis C, Iztueta I, de Torres I, Oliván M, Reventós J, Doll A. Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes. Actas Urol Esp 2014; 38:232-7. [PMID: 24156935 DOI: 10.1016/j.acuro.2013.09.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 09/08/2013] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To analyze the influence of sedentary (SE) and overweight (OW) in the risk of prostate cancer detection (CP) and aggressiveness. MATERIAL AND METHOD We performed prostate biopsy (PB) to 2,408 consecutive male, 5 ARIs untreated, because of elevated serum PSA above 4.0 ng/mL (91%) or suspicious digital rectal examination (9%). In all ultrasound guided PB, 10 cores were obtained plus 2 to 8 additionals, according to age and prostate volume. Physical activity was assessed using a survey (SE vs non-SE) and calculated body mass index (normal vs OW > 25 kg/cm(2)). The tumor aggressiveness was evaluated according to the Gleason score (high grade «HG»: Gleason > 7) and D'Amico risk (high risk «HR»: T > 3a or PSA > 20 or Gleason score > 7). RESULTS We found a significant association between SE (52.5%) and OW (72.9%), P < .001. The overall PC detection rate was 35.2%. In men with SE it was 36.7% and non-SE 33.6%, P = .048. The overall rate of AG tumors was 28.3%, 29.2% in men with SE and 27.1 in non-SE, P = .261. The overall rate of AR tumors was 35%, 39.7% in men with SE and 29.4% non-SE, P < .001. CP was detected in 38.1% of men with normal BMI and 34.3% in men with OW, P = .065. HG tumor rates were 18.1% and 31.4% respectively, P < .001 and AR tumor rates were 22.6% and 39.2% respectively, P < .001. Binary logistic regression showed that SE was an independent predictor of CP, OR .791 (95% CI: .625-.989), P = .030. SE and OW were independent predictors of HG: OR .517 (95% CI: .356-.752), P = .001, and OR 1.635 (95% CI: 1070-2497), p = 0.023. SE and OW were also independent predictors of HR: OR .519 (95% CI .349-.771), P = .001, and OR 1.998 (95% CI 1.281-3.115), P = .002. CONCLUSIONS In men who met criteria for prostate biopsy an association between sedentary and overweight exist. A sedentary lifestyle is associated with increased risk of PC detection while sedentary and overweight were associated with more aggressive tumors.
Collapse
|
27
|
Garcia M, Velez R, Romagosa C, Majem B, Pedrola N, Olivan M, Rigau M, Guiu M, Gomis RR, Morote J, Reventós J, Doll A. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014; 113:E164-77. [DOI: 10.1111/bju.12503] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Marta Garcia
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Roberto Velez
- Universitat Autònoma de Barcelona; Barcelona Spain
- Orthopaedic Surgery and Traumatology Department; Vall d'Hebron University Hospital; Barcelona Spain
| | - Cleofé Romagosa
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Pathology; Vall d'Hebron University Hospital; Barcelona Spain
| | - Blanca Majem
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Núria Pedrola
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Orthopaedic Surgery and Traumatology Department; Vall d'Hebron University Hospital; Barcelona Spain
| | - Marina Rigau
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Marc Guiu
- Oncology Programme; Institute for Research in Biomedicine (IRB-Barcelona); Barcelona Spain
| | - Roger R. Gomis
- Oncology Programme; Institute for Research in Biomedicine (IRB-Barcelona); Barcelona Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA); Barcelona Spain
| | - Juan Morote
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Urology; Vall d'Hebron University Hospital; Barcelona Spain
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Basic Science; International University of Catalonia; Barcelona Spain
| | - Andreas Doll
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Department of Basic Science; International University of Catalonia; Barcelona Spain
| |
Collapse
|
28
|
Bonifaci N, Colas E, Serra-Musach J, Karbalai N, Brunet J, Gómez A, Esteller M, Fernández-Taboada E, Berenguer A, Reventós J, Müller-Myhsok B, Amundadottir L, Duell EJ, Pujana MÀ. Integrating gene expression and epidemiological data for the discovery of genetic interactions associated with cancer risk. Carcinogenesis 2013; 35:578-85. [PMID: 24296589 DOI: 10.1093/carcin/bgt403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Dozens of common genetic variants associated with cancer risk have been identified through genome-wide association studies (GWASs). However, these variants only explain a modest fraction of the heritability of disease. The missing heritability has been attributed to several factors, among them the existence of genetic interactions (G × G). Systematic screens for G × G in model organisms have revealed their fundamental influence in complex phenotypes. In this scenario, G × G overlap significantly with other types of gene and/or protein relationships. Here, by integrating predicted G × G from GWAS data and complex- and context-defined gene coexpression profiles, we provide evidence for G × G associated with cancer risk. G × G predicted from a breast cancer GWAS dataset identified significant overlaps [relative enrichments (REs) of 8-36%, empirical P values < 0.05 to 10(-4)] with complex (non-linear) gene coexpression in breast tumors. The use of gene or protein data not specific for breast cancer did not reveal overlaps. According to the predicted G × G, experimental assays demonstrated functional interplay between lipoma-preferred partner and transforming growth factor-β signaling in the MCF10A non-tumorigenic mammary epithelial cell model. Next, integration of pancreatic tumor gene expression profiles with pancreatic cancer G × G predicted from a GWAS corroborated the observations made for breast cancer risk (REs of 25-59%). The method presented here can potentially support the identification of genetic interactions associated with cancer risk, providing novel mechanistic hypotheses for carcinogenesis.
Collapse
Affiliation(s)
- Núria Bonifaci
- Breast Cancer and Systems Biology Unit, Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Lanau L, Rigau M, Majem B, Altadill T, Castellví J, Sánchez-Iglesias JL, Pérez-Benavente A, Cabrera S, García A, Xercavins J, Campo JMD, Gil-Moreno A, Ruiz A, Reventós J, Llauradó M. Abstract B15: Unveiling the mechanism of ovarian cancer dissemination through a comparative study among primary tumors, ascites and metastases. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-b15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Epithelial ovarian cancer (OC) is the most lethal gynecological malignancy and the fifth cause of cancer deaths in women in the western world. Largely asymptomatic, OC is frequently detected at late stage (75-80%). Five-year survival rate for women with advanced stage disease is less than 20%, while the cure rate is almost 90% when are diagnosed at early stages. Epithelial OC metastasizes by direct extension from the ovary seeding the cells into the peritoneal wall and to neighbouring organs. Our aim is to study the OC dissemination comparing human paired ovarian primary tumors, ascites and metastases.
Material & Methods: Fresh ovarian primary tumor, ascites and peritoneal metastases from patients suffering advanced serous OC were collected at the surgery room and processed for further analysis. Formalin-fixed paraffin-embedded (FFPE) tissues were collected from the Pathology Department for further immunohistochemical analysis. Discovery phase: We determined the global gene expression profile of 5 fresh-paired samples (primary tumor, ascites and metastases) by microarray analysis. Validation phase: We analysed mRNA and protein levels from 10 unpaired fresh samples by RTqPCR and Western-blot, respectively. We further evaluated protein expression by immunohistochemistry from 10-paired tumor and metastasis FFPE-samples.
Results: GREM1 was shown to be upregulated in metastases versus ascites and in metastases versus primary tumors. FABP4 and INHBA were significantly overexpressed in metastases when compared to primary tumors. INHBA and FABP4 were validated at RNA and protein level, whereas GREM1 only at RNA level.
Conclusions: The present study highlights the role of previously unknown candidates in OC dissemination that might be used as tumor biomarkers, to clinically monitor the progression of the disease, or as target therapies, to block the OC dissemination.
Citation Format: Lucia Lanau, Marina Rigau, Blanca Majem, Tatiana Altadill, Josep Castellví, José-Luis Sánchez-Iglesias, Assumpció Pérez-Benavente, Silvia Cabrera, Angel García, Jordi Xercavins, Josep-Maria Del Campo, Antonio Gil-Moreno, Anna Ruiz, Jaume Reventós, Marta Llauradó. Unveiling the mechanism of ovarian cancer dissemination through a comparative study among primary tumors, ascites and metastases. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr B15.
Collapse
Affiliation(s)
- Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Josep Castellví
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | | | - Assumpció Pérez-Benavente
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Silvia Cabrera
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Angel García
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Jordi Xercavins
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Josep-Maria Del Campo
- 4Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain
| | - Antonio Gil-Moreno
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Anna Ruiz
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Marta Llauradó
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| |
Collapse
|
30
|
Altadill T, Rigau M, Majem B, Lanau L, Castellví J, García Á, Pérez-Benavente A, Sánchez JL, Cabrera S, Xercavins J, Campo JMD, Gil-Moreno A, Llauradó M, Reventós J. Abstract A28: Analyses of FOXM1 isoforms in ovarian cancer. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-a28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Epithelial ovarian cancer (OC) is the most lethal gynaecological malignancy and the fifth leading cause of cancer death in women in the Western world. Forkhead box M1 (FOXM1) transcription factor was already been described to be overexpressed in various malignancies, playing a key role in cell-cycle progression, chromosomal segregation and genomic stability, and oxidative stress. Moreover, it can also promote drug resistance to herceptin, paclitaxel and cisplatin in breast cancer cells. A recent report from our group has shown, for the first time, that FOXM1 is also overexpressed in OC, being associated with tumor grade. This result seem to indicate an interesting role of this molecule in the progression and resistance to therapy in OC. Our aim is to characterize FOXM1 isoforms in OC through the use of human tissue samples.
Material & Methods: Fresh ovarian primary tumors, ascites and peritoneal metastases from patients suffering advanced serous OC were collected from surgery room and processed for microarray analysis to detect FOXM1 expression levels. FOXM1 isoforms were analysed at mRNA expression level by using RTqPCR in a set of new frozen tissue samples.
Results: We found that FOXM1 overexpression is increased in OC peritoneal metastases. Now, we are characterizing the isoforms of FOXM1 in primary, ascites and metastatic tumors. Nevertheless, more samples need to be analysed in order to have conclusive results.
Conclusions: The present study highlights the role of FOXM1 isoforms in OC dissemination and pursues the idea to elucidate the biologic role of FOXM1 in OC tumorigenesis.
Citation Format: Tatiana Altadill, Marina Rigau, Blanca Majem, Lucia Lanau, Josep Castellví, Ángel García, Assumpció Pérez-Benavente, José Luis Sánchez, Silvia Cabrera, Jordi Xercavins, Josep Maria del Campo, Antonio Gil-Moreno, Marta Llauradó, Jaume Reventós. Analyses of FOXM1 isoforms in ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A28.
Collapse
Affiliation(s)
- Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Josep Castellví
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Ángel García
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | | | - José Luis Sánchez
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Silvia Cabrera
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Jordi Xercavins
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Josep Maria del Campo
- 4Department of Medical Oncology, Gynecological and Head and Neck Tumors, Vall d'Hebron Institute of O, Barcelona, Spain,
| | - Antonio Gil-Moreno
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Marta Llauradó
- 5Medical University, University of British Columbia, Vancouver, Canada
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| |
Collapse
|
31
|
Rigau M, Majem B, Altadill T, Lanau L, Sánchez-Iglesias JL, Castellví J, Pérez-Benavente A, Cabrera S, García A, Xercavins J, Alameda F, Matias-Guiu X, Gil-Moreno A, Campo JMD, Llauradó M, Reventós J. Abstract A56: Identification of a micro RNA profile to predict response to therapy and improve patient survival in ovarian cancer. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-a56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Ovarian cancer (OC) is the leading cause of death among gynecological malignancies in developed countries. The standard treatment is surgery plus platinum-paclitaxel (CP/TX) chemotherapy. Nevertheless, 70% of these patients are diagnosed in advanced stages, and, among those, 75% will recur, become resistant to therapies and die. We believe that an improvement in OC survival might be related with an early identification of those patients, since long survival (SV) is related to chemosensitivity. Our aim is to identify an expression profile of micro RNAs (miRNAs) associated with SV of patients with advanced OC.
Material & Methods: Formalin-fixed paraffin-embedded (FFPE) primary tumor tissues from late stage (III/IV) OC patients were collected at the time of surgery for the study. All patients were treated with optimal surgery and standard chemotherapy (CP/TX; after surgery). Samples were divided into two groups; (a) patients with “long SV” (SV>10 years after diagnosis) and (b) patients with “short SV”. The identification of miRNAs associated with each profile of SV was performed using TaqMan Array MicroRNA microfluidic cards in 30 patients.
Results: The identification phase has shown that the majority of the miRNAs appeared to be down-regulated in the group of “short SV” versus the “long SV”. A validation phase in a new group of tumor tissue samples is ready to validate the promising miRNA candidates that seem to be associated with the resistant (short SV) and the sensitive (long SV) profiles.
Conclusions: The ability to identify markers associated with “long SV” in patients with advanced OC could allow transforming the impact of the disease through the reduction of chemotherapy treatments and the reduction of unnecessary health care costs. Moreover, it could permit the generation of knowledge applicable to the future development of new therapies for the “short SV” since they are supposed to be resistant to the therapy.
Citation Format: Marina Rigau, Blanca Majem, Tatiana Altadill, Lucia Lanau, José-Luis Sánchez-Iglesias, Josep Castellví, Assumpció Pérez-Benavente, Silvia Cabrera, Angel García, Jordi Xercavins, Francesc Alameda, Xavier Matias-Guiu, Antonio Gil-Moreno, Josep-Maria Del Campo, Marta Llauradó, Jaume Reventós. Identification of a micro RNA profile to predict response to therapy and improve patient survival in ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A56.
Collapse
Affiliation(s)
- Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | | | - Josep Castellví
- 3Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Assumpció Pérez-Benavente
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Silvia Cabrera
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Angel García
- 3Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Jordi Xercavins
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Francesc Alameda
- 4Pathology Department, Hospital del Mar, Barcelona, Barcelona, Spain,
| | - Xavier Matias-Guiu
- 5Pathology Department, Hospital Arnau de Vilanova, Lleida, Lleida, Spain,
| | - Antonio Gil-Moreno
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Josep-Maria Del Campo
- 6Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain
| | - Marta Llauradó
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| |
Collapse
|
32
|
Perez-Sanchez C, Colas E, Cabrera S, Falcon O, Sanchez-del-Río A, García E, Fernández-de-Castillo L, Muruzabal JC, Alvarez E, Fiol G, González C, Torrejón R, Moral E, Campos M, Repollés M, Carreras R, Jiménez-López J, Xercavins J, Aibar E, Perdones-Montero A, Lalanne E, Palicio M, Maes T, Rosell-Vives E, Nieto C, Ortega A, Pedrola N, Llauradó M, Rigau M, Doll A, Abal M, Ponce J, Gil-Moreno A, Reventós J. Molecular diagnosis of endometrial cancer from uterine aspirates. Int J Cancer 2013; 133:2383-91. [DOI: 10.1002/ijc.28243] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 03/28/2013] [Accepted: 04/09/2013] [Indexed: 11/08/2022]
Affiliation(s)
| | - Eva Colas
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Vall d'Hebron Research Institute and Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Silvia Cabrera
- Department of Gynecological Oncology; Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Orlando Falcon
- REDITOG Network; Hospital Universitario Materno Infantil de Canarias; Las Palmas de Gran Canaria; Spain
| | | | - Enrique García
- REDITOG Network; Fundación Instituto Valenciano de Oncología; Valencia; Spain
| | - Luis Fernández-de-Castillo
- REDITOG Network; University Hospital of Bellvitge-HUB; Bellvitge Research Institute-IDIBELL; Barcelona; Spain
| | | | - Elena Alvarez
- REDITOG Network; Hospital Universitari Josep Trueta; Girona; Spain
| | - Gabriel Fiol
- REDITOG Network; Complejo Hospitalario Torrecárdenas; Almería; Spain
| | - Carmen González
- REDITOG Network, Hospital de Viladecans; Biomedical Institute Research; Viladecans; Barcelona; Spain
| | - Rafael Torrejón
- REDITOG Network; Hospital Universitario Virgen del Rocío; Sevilla; Spain
| | - Eloy Moral
- REDITOG Network; Hospital Provincial de Pontevedra; Pontevedra; Spain
| | - Miriam Campos
- REDITOG Network; University Hospital of Bellvitge-HUB; Bellvitge Research Institute-IDIBELL; Barcelona; Spain
| | - Manuel Repollés
- Department of Gynecology and Obstetrics; Hospital Ramon y Cajal; Madrid; Spain
| | - Ramon Carreras
- Service of Obstetrics and Gynecology; Hospital Universitari del Mar and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Jesus Jiménez-López
- Department of Gynecological Oncology; Hospital Universitario 12 de Octubre; Madrid; Spain
| | - Jordi Xercavins
- Department of Gynecological Oncology; Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Elena Aibar
- Oryzon Genomics; Cornellà de Llobregat; Barcelona; Spain
| | | | - Eric Lalanne
- Oryzon Genomics; Cornellà de Llobregat; Barcelona; Spain
| | - Marta Palicio
- Oryzon Genomics; Cornellà de Llobregat; Barcelona; Spain
| | - Tamara Maes
- Oryzon Genomics; Cornellà de Llobregat; Barcelona; Spain
| | | | - Carlos Nieto
- Reig Jofre Group, Sant Joan Despí; Barcelona; Spain
| | | | - Nuria Pedrola
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Vall d'Hebron Research Institute and Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Marta Llauradó
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Vall d'Hebron Research Institute and Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Marina Rigau
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Vall d'Hebron Research Institute and Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Andreas Doll
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Vall d'Hebron Research Institute and Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | - Miguel Abal
- Translational Laboratory/Medical Oncology Department; Complexo Hospitalario Universitario de Santiago/SERGAS; Santiago de Compostela; Spain
| | - Jordi Ponce
- REDITOG Network; University Hospital of Bellvitge-HUB; Bellvitge Research Institute-IDIBELL; Barcelona; Spain
| | - Antonio Gil-Moreno
- Department of Gynecological Oncology; Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona; Barcelona; Spain
| | | |
Collapse
|
33
|
Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, Llauradó M, Planas J, de Torres I, Morote J, Cooper C, Reventós J, Clark J, Doll A. The present and future of prostate cancer urine biomarkers. Int J Mol Sci 2013; 14:12620-49. [PMID: 23774836 PMCID: PMC3709804 DOI: 10.3390/ijms140612620] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Revised: 05/27/2013] [Accepted: 06/03/2013] [Indexed: 11/30/2022] Open
Abstract
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput “omic” techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Collapse
Affiliation(s)
- Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Marta Garcia
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Tamara Sequeiros
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Melania Montes
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Eva Colás
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Marta Llauradó
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
| | - Jacques Planas
- Department of Urology, Vall d’Hebron University Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (J.P.); (J.M.)
| | - Inés de Torres
- Department of Pathology, Vall d’Hebron University Hospital Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mail:
| | - Juan Morote
- Department of Urology, Vall d’Hebron University Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (J.P.); (J.M.)
| | - Colin Cooper
- Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
- Department of Basic Sciences, International University of Catalonia, 08017 Barcelona, Spain
| | - Jeremy Clark
- Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)
| | - Andreas Doll
- Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain; E-Mails: (M.R.); (M.O.); (M.G.); (T.S.); (M.M.); (E.C.); (M.L.); (J.R.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +34-93-489-4067; Fax: +34-93-274-6708
| |
Collapse
|
34
|
Doll A, García M, Rigau M, Olivan M, Montes M, Sequeiros T, Llaurado M, Colás E, Reventós J, Morote J. [Molecular biology of bone metastases]. ARCH ESP UROL 2013; 66:463-474. [PMID: 23793764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Bone metastases are a frequent and devastating complication in cancer patients. Recently, significant advances in our understanding of the molecular mechanisms responsible for both osteolytic and osteoblastic bone metastases have occurred. The use of OMICS and the availability of appropriate preclinical animal models of bone metastasis have permitted the identification of factors produced by the tumor or by the host stroma in response to the tumor. These types of studies should result in a decrease of the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. In this review the next generation of molecular targets in bone metastasis will be summarized.
Collapse
Affiliation(s)
- Andreas Doll
- Programa de Investigación Traslacional en Cáncer de Próstata Vall d'Hebrón, Hospital Vall d'Hebrón. Barcelona, España.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tirado OM, Selva DM, Toràn N, Suárez-Quian CA, Jansen M, McDonnell DP, Reventós J, Munell F. Increased Expression of Estrogen Receptor β in Pachytene Spermatocytes After Short-Term Methoxyacetic Acid Administration. ACTA ACUST UNITED AC 2013; 25:84-94. [PMID: 14662790 DOI: 10.1002/j.1939-4640.2004.tb02762.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Degeneration of primary spermatocytes by apoptosis occurs during normal spermatogenesis, as well as in several pathological conditions, including exposure to specific testicular toxicants. The mechanisms that regulate the death and survival of primary spermatocytes, however, are still not well understood. The recent localization of estrogen receptor beta (ERbeta) and P450 aromatase in pachytene spermatocytes suggests a role for estrogens in this step of spermatogenesis. Using a well-known model of pachytene spermatocyte apoptosis in adult rats consisting of the administration of methoxyacetic acid (MAA), we investigated the participation of ERbeta during the initial phase of apoptosis, prior to germ cell loss. Adult rats were treated with a single intraperitoneal dose of MAA, and DNA laddering analysis confirmed apoptotic cell death in the testis. In enriched germ cell fractions and testis from MAA-treated animals, ERbeta mRNA increased significantly at 3 and 6 hours, respectively. Next, stage-specific induction of ERbeta mRNA was demonstrated by use of laser capture microdissection of seminiferous tubules in combination with semiquantitative reverse transcription-polymerase chain reaction. The ERbeta protein also increased significantly after 6 hours and was mainly immunolocalized in the cytoplasm of pachytene spermatocytes of afflicted tubules. The cytoplasmic localization was confirmed by Western blot analysis of isolated cytoplasmic and nuclear fractions of testicular extracts. Finally, the MAA activation of ERbeta was tested in vitro in HepG2 cells cotransfected with ERbeta and a reporter construct that contained a consensus estrogen responsive element. Addition of MAA at similar doses used in vivo elicited a similar estrogenic activation as did estradiol at 1 nmol/L concentration. The present results raise the possibility that cytoplasmic ERbeta participates in the apoptotic process of pachytene spermatocytes induced by MAA. Whether MAA interacts with ERbeta in the cytoplasm of primary spermatocytes, preventing the progression of the first meiotic division, however, remains to be determined.
Collapse
Affiliation(s)
- Oscar M Tirado
- Unitat de Recerca Biomèdica, Hospital Materno-Infantil Vall d'Hebron, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Ramón y Cajal S, Mooseker MS, Mariadason JM, Gebert J, Hofstra RMW, Reventós J, Yamamoto H, Schwartz S, Arango D. Brush border myosin Ia inactivation in gastric but not endometrial tumors. Int J Cancer 2012; 132:1790-9. [PMID: 23002058 DOI: 10.1002/ijc.27856] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Accepted: 08/09/2012] [Indexed: 12/17/2022]
Abstract
Brush border Myosin Ia (MYO1A) has been shown to be frequently mutated in colorectal tumors with microsatellite instability (MSI) and to have tumor suppressor activity in intestinal tumors. Here, we investigated the frequency of frameshift mutations in the A8 microsatellite in exon 28 of MYO1A in MSI gastric and endometrial tumors and found a high mutation rate in gastric (22/47; 46.8%) but not endometrial (3/48; 6.2%) tumors. Using a regression model, we show that MYO1A mutations are likely to confer a growth advantage to gastric, but not endometrial tumors. The mutant MYO1A(7A) protein was shown to lose its membrane localization in gastric cancer cells and a cycloheximide-chase assay demonstrated that the mutant MYO1A(7A) protein has reduced stability compared to the wild type MYO1A. Frequent MYO1A promoter hypermethylation was also found in gastric tumors. Promoter methylation negatively correlates with MYO1A mRNA expression in a series of 58 non-MSI gastric primary tumors (Pearson's r = -0.46; p = 0.0003) but not in a cohort of 54 non-MSI endometrial tumors and treatment of gastric cancer cells showing high MYO1A promoter methylation with the demethylating agent 5-aza-2'-deoxycytidine, resulted in a significant increase of MYO1A mRNA levels. We found that normal gastric epithelial cells, but not normal endometrial cells, express high levels of MYO1A. Therefore, when considered together, our findings suggest that MYO1A has tumor suppressor activity in the normal gastric epithelium but not in the normal endometrium and inactivation of MYO1A either genetically or epigenetically may confer gastric epithelial cells a growth advantage.
Collapse
Affiliation(s)
- Rocco Mazzolini
- Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2012; 111:1031-6. [PMID: 22883053 DOI: 10.1111/j.1464-410x.2012.11406.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
UNLABELLED WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Metabolic syndrome can identify patients at high risk of cardiovascular disease. The prevalence of metabolic syndrome is increasing worldwide and is associated with increased age, obesity and hypogonadism. The association between metabolic syndrome and prostate cancer development has not been studied comprehensively, and published studies report divergent results. This study indicates that tumours detected in men with metabolic syndrome are more aggressive than those detected in men without this condition. OBJECTIVE To further examine the association between metabolic syndrome (MS), prostate cancer (PC) detection risk and tumour aggressiveness. PATIENTS AND METHODS From 2006 to 2010, 2408 men not receiving 5α-reductase inhibitors were scheduled for prostatic biopsy due to PSA above 4 ng/mL and/or abnormal digital rectal examination. MS was evaluated according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition. Tumour aggressiveness was evaluated through biopsy Gleason score, clinical stage and risk of biochemical recurrence after primary treatment. RESULTS The rates of PC detection were 34.5% and 36.4% respectively in men with and without MS, P = 0.185. High grade PC rates (Gleason score 8-10) were 35.9% and 23.9% respectively, P < 0.001. The advanced disease rates (cT3-4 N0-1 M0-1) were 17% and 12.7% respectively, P = 0.841. The high risk PC rates (cT2c-4 or Gleason score 8-10 or PSA > 20) were 38.5% and 33.0% respectively, P = 0.581. Multivariate analysis confirmed that MS was not associated with the risk of PC detection but it was associated with an increased risk of high grade tumours (odds ratio 1.75, 95% CI 1.26-2.41), P < 0.001. CONCLUSION MS seems not be associated with an increased risk of PC detection but it is associated with an increased risk of more aggressive tumours.
Collapse
Affiliation(s)
- Juan Morote
- Department of Urology, Universitat Autónoma de Barcelona, Paseo Vall d'Hebron 119-129, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón y Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol 2012; 358:244-55. [PMID: 22037169 DOI: 10.1016/j.mce.2011.10.003] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 09/30/2011] [Accepted: 10/04/2011] [Indexed: 12/31/2022]
Abstract
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.
Collapse
Affiliation(s)
- Marta Llauradó
- Biomedical Research Unit, Vall d'Hebron Research Institute and University Hospital, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Llauradó M, Majem B, Castellví J, Cabrera S, Gil-Moreno A, Reventós J, Ruiz A. Analysis of Gene Expression Regulated by the ETV5 Transcription Factor in OV90 Ovarian Cancer Cells Identifies FOXM1 Overexpression in Ovarian Cancer. Mol Cancer Res 2012; 10:914-24. [DOI: 10.1158/1541-7786.mcr-11-0449] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Quiles M, Arbós M, De Torres I, Blázquez C, Reventós J, Morote J. 848 Differential gene expression profiling in proliferative inflammatory atrophia compared to prostate carcinoma and high grade prostatic intraneoplasia using frozen microdissected tissues. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/s1569-9056(12)60845-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Cabrera S, Llauradó M, Castellví J, Fernandez Y, Alameda F, Colás E, Ruiz A, Doll A, Schwartz S, Carreras R, Xercavins J, Abal M, Gil-Moreno A, Reventós J. Generation and characterization of orthotopic murine models for endometrial cancer. Clin Exp Metastasis 2011; 29:217-27. [PMID: 22198674 DOI: 10.1007/s10585-011-9444-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2011] [Accepted: 12/07/2011] [Indexed: 11/25/2022]
Abstract
We describe the generation of two orthotopic murine models for endometrial cancer (EC).The first model is generated from endometrial Hec-1A cancer cells transfected with luciferase and injected directly into the uterus of female mice. This model allows a follow-up with bioluminescence imaging (BLI) along the experiment and generates abdominal dissemination and lymphatic and hematogenous metastases in high percentages, also detectables with BLI. The dissemination pattern of this model imitates the advanced stages of EC in patients, and its molecular profile corresponds to aggressive type 2 EC (p53 positive, hormone receptors negative, high percentage of Ki67 positive cells). The second model is derived from endometrioid human tissue collected from surgical pieces. By injecting this tissue inside the uterine cavity of a mouse we obtain orthotopic growth with pelvic dissemination and lymph node metastasis. The molecular pattern observed in human type 1 endometrioid EC (p53 negative, low Ki67 index, presence of hormone receptors) is conserved after the murine growth in orthotopic tumor and metastases. This model supposes a singular pre-clinical tool to study therapeutic agents, though it mimics clinical and molecular behavior of endometrioid EC, which is the most common histology in the patient.
Collapse
Affiliation(s)
- Silvia Cabrera
- Department of Gynecology, Hospital Vall d'Hebron, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011; 71:1736-45. [PMID: 21520154 DOI: 10.1002/pros.21390] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 03/07/2011] [Indexed: 12/18/2022]
Abstract
BACKGROUND Several studies have demonstrated the usefulness of monitoring an RNA transcript, such as PCA3, in post-prostate massage (PM) urine for increasing the specificity of prostate-specific antigen (PSA) in the detection of prostate cancer (PCa). However, a single marker may not necessarily reflect the multifactorial nature of PCa. METHODS We analyzed post-PM urine samples from 154 consecutive patients, who presented for prostate biopsies because of elevated serum PSA (>4 ng/ml) and/or abnormal digital rectal exam. We tested whether the putative PCa biomarkers PSMA, PSGR, and PCA3 could be detected by quantitative real-time PCR in post-PM urine sediment. We combined these findings to test if a combination of these biomarkers could improve the specificity of actual diagnosis. Afterwards, we specifically tested our model for clinical usefulness in the PSA diagnostic "gray zone" (4-10 ng/ml) on a target subset of 82 men with no prior biopsy. RESULTS By univariate analysis, we found that the PSMA, PSGR, and PCA3 scores were significant predictors of PCa. Using a multiplex model, the area under the multi receiver-operating characteristic curve was 0.74 versus 0.82 in the diagnostic "gray zone." Fixing the sensitivity at 96%, we obtained a specificity of 34% and 50% in the gray zone. CONCLUSIONS Taken together, these results provide a strategy for the development of a more accurate model for PCa diagnosis. In the future, a multiplexed, urine-based diagnostic test for PCa with a higher specificity, but the same sensitivity as the serum-PSA test, could be used to determine better which patients should undergo biopsy.
Collapse
Affiliation(s)
- Marina Rigau
- Research Unit in Biomedicine and Translational and Pediatric Oncology, Vall d'Hebron Research Institute, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Llauradó M, Abal M, Castellví J, Cabrera S, Gil-Moreno A, Pérez-Benavente A, Colás E, Doll A, Dolcet X, Matias-Guiu X, Vazquez-Levin M, Reventós J, Ruiz A. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer 2011; 130:1532-43. [DOI: 10.1002/ijc.26148] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2010] [Accepted: 03/29/2011] [Indexed: 12/30/2022]
|
44
|
Quiles MT, Arbós MA, de Torres IM, Reventós J, Morote J. 270 DIFFERENTIAL CHEMOKINE GENE EXPRESSION PROFILE IN PROSTATE CANCER-ASSOCIATED FIBROBLASTS. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Fernández S, Mosquera JL, Alaña L, Sanchez-Pla A, Morote J, Ramón Y Cajal S, Reventós J, de Torres I, Paciucci R. PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Arch 2010; 458:323-30. [PMID: 21181414 DOI: 10.1007/s00428-010-1018-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Revised: 11/22/2010] [Accepted: 11/23/2010] [Indexed: 12/19/2022]
Abstract
The prostate tumor overexpressed-1 (PTOV1) protein was first described overexpressed in prostate cancer but not detected in normal prostate. PTOV1 expression is associated to increased cancer proliferation in vivo and in vitro. In prostate biopsy, PTOV1 detection is helpful in the early diagnosis of cancer. The purpose of this study was to analyze the relevance of PTOV1 expression to identify aggressive tumors derived from 12 different histological tissues. Tissue microarrays (TMAs) containing 182 biopsy samples, including 168 human tumors, were analyzed for PTOV1 and Ki67 expression by immunohistochemistry. Tumors of low and high histological grade were selected from lung, breast, endometrium, pancreas liver, skin, ovary, colon, stomach, kidney, bladder, and cerebral gliomas. One TMA with representative tissues without cancer (14 samples) was used as control. PTOV1 expression was analyzed semiquantitatively for the intensity and percentage of positive cells. Ki67 was evaluated for tumors proliferative index. Results show that PTOV1 was expressed in over 95% of tumors examined. Its expression was significantly associated to high-grade tumors (p = 0.014). This association was most significant in urothelial bladder carcinomas (p = 0.026). Overall, the expression of Ki67 was associated to high-grade tumors, and it was significant in several tumor types. PTOV1 and Ki67 were significantly co-overexpressed in all tumors (p = 0.001), and this association was significant in clear cell renal carcinoma (p = 0.005). In conclusion, PTOV1 expression is associated to more aggressive human carcinomas and more significantly to bladder carcinomas suggesting that this protein is a potential new marker of aggressive disease in the latter tumors.
Collapse
Affiliation(s)
- Sara Fernández
- Department of Pathology, Vall Hebron Hospital, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Roma J, Masià A, Reventós J, Sánchez de Toledo J, Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 2010; 17:505-13. [PMID: 21177409 DOI: 10.1158/1078-0432.ccr-10-0166] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal and alveolar RMS. Patients with metastatic disease continue to have very poor prognosis although aggressive therapies and recurrences are common in advanced localized disease. The oncogenic potential of the Notch pathway has been established in some cancers of the adult and in some pediatric malignancies. EXPERIMENTAL DESIGN A real-time PCR assay was used to ascertain the expression of several Notch pathway components in a wide panel of RMS and cell lines. Four γ-secretase inhibitors (GSIs) were tested for pathway inhibition and the degree of inhibition was assessed by analysis of Hes1 and Hey1 expression. The putative effects of Notch pathway inhibition were evaluated by wound-healing, matrigel/transwell invasion, cell-cycle, and apoptosis assays. RESULTS The Notch pathway was widely expressed and activated in RMS and underwent substantial inhibition when treated with GSIs or transfected with a dominant negative form of MAML1. RMS cells showed a significant decrease in its mobility and invasiveness when the Notch pathway was properly inhibited; conversely, its inhibition had no noticeable effect on cell cycle or apoptosis. CONCLUSION Pharmacological or genetic blockage of the pathway significantly reduced invasiveness of RMS cell lines, thereby suggesting a possible role of the Notch pathway in the regulation of the metastatic process in RMS.
Collapse
Affiliation(s)
- Josep Roma
- Biomedical Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | | | | | | | | |
Collapse
|
47
|
Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colás E, Garcia M, Ruiz A, Abal M, Planas J, Reventós J, Doll A. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010; 70:1760-7. [PMID: 20672322 DOI: 10.1002/pros.21211] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Several studies have demonstrated the usefulness of monitoring an RNA transcript in urine, such as PCA3, for prostate cancer (PCa) diagnosis. PCa screening would benefit from additional biomarkers of higher specificity and could be used in conjunction with prostate-specific antigen (PSA) testing, in order to better determine biopsy candidates. METHODS We used urine sediments after prostate massage (PM) from 215 consecutive patients, who presented for prostate biopsy. We tested whether prostate-specific G-protein coupled receptor (PSGR), a biomarker previously described to be over-expressed in PCa tissue, could also be detected by quantitative real-time PCR in post-PM urine sediment. We combined these findings with prostate cancer gene 3 (PCA3), the current gold standard for PCa diagnosis in urine, to test if a combination of both biomarkers could improve the sensitivity of PCA3 alone. RESULTS By univariate analysis we found that PSGR and PCA3 were significant predictors of PCa. Receiver operator characteristic curve analysis and its multivariate extension, multivariate ROC (MultiROC), were used to assess the outcome predictive values of the individual and the paired biomarkers. We obtained the following area under the curve values: PSA (0.602), PSGR (0.681), PCA3 (0.656), and PSGRvPCA3 (0.729). Then, we tested whether a combination of PSGR and PCA3 could improve specificity by fixing the sensitivity at 95%. We obtained specificities of 15% (PSGR), 17% (PCA3), and 34% (PSGRvPCA3). CONCLUSIONS A multiplexed model including PSGR and PCA3 improves the specificity for the detection of PCa, especially in the area of high sensitivity. This could be clinically useful for determining which patients should undergo biopsy.
Collapse
Affiliation(s)
- Marina Rigau
- Biomedical Research Unit, Research Institute, Vall d'Hebron UniversityHospital, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Pinós T, Barbosa-Desongles A, Hurtado A, Santamaria-Martínez A, de Torres I, Reventós J, Munell F. Human SHBG mRNA translation is modulated by alternative 5'-non-coding exons 1A and 1B. PLoS One 2010; 5:e13844. [PMID: 21079794 PMCID: PMC2973947 DOI: 10.1371/journal.pone.0013844] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2010] [Accepted: 10/06/2010] [Indexed: 11/30/2022] Open
Abstract
Background The human sex hormone-binding globulin (SHBG) gene comprises at least 6 different transcription units (TU-1, -1A, -1B, -1C, -1D and -1E), and is regulated by no less than 6 different promoters. The best characterized are TU-1 and TU-1A: TU-1 is responsible for producing plasma SHBG, while TU-1A is transcribed and translated in the testis. Transcription of the recently described TU-1B, -1C, and -1D has been demonstrated in human prostate tissue and prostate cancer cell lines, as well as in other human cell lines such as HeLa, HepG2, HeK 293, CW 9019 and imr 32. However, there are no reported data demonstrating their translation. In the present study, we aimed to determine whether TU-1A and TU-1B are indeed translated in the human prostate and whether 5′ UTR exons 1A and 1B differently regulate SHBG translation. Results Cis-regulatory elements that could potentially regulate translation were identified within the 5′UTRs of SHBG TU-1A and TU–1B. Although full-length SHBG TU-1A and TU-1B mRNAs were present in prostate cancer cell lines, the endogenous SHBG protein was not detected by western blot in any of them. LNCaP prostate cancer cells transfected with several SHBG constructs containing exons 2 to 8 but lacking the 5′UTR sequence did show SHBG translation, whereas inclusion of the 5′UTR sequences of either exon 1A or 1B caused a dramatic decrease in SHBG protein levels. The molecular weight of SHBG did not vary between cells transfected with constructs with or without the 5′UTR sequence, thus confirming that the first in-frame ATG of exon 2 is the translation start site of TU-1A and TU-1B. Conclusions The use of alternative SHBG first exons 1A and 1B differentially inhibits translation from the ATG situated in exon 2, which codes for methionine 30 of transcripts that begin with the exon 1 sequence.
Collapse
Affiliation(s)
- Tomàs Pinós
- Institut de Recerca Hospital Universitari Vall d'Hebrón, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain
| | | | - Antoni Hurtado
- Institut de Recerca Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | | | - Inés de Torres
- Servei d'Anatomía Patològica, Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | - Jaume Reventós
- Institut de Recerca Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | - Francina Munell
- Institut de Recerca Hospital Universitari Vall d'Hebrón, Barcelona, Spain
- * E-mail:
| |
Collapse
|
49
|
Muinelo-Romay L, Colas E, Gil-Moreno A, Barbazán J, Alonso-Alconada L, Curiel T, Cuevas J, Reventós J, López-López R, Abal M. 159 TGF-β1 as a therapeutic target in high risk endometrial carcinomas. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71864-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
50
|
Gallardo-Arrieta F, Doll A, Rigau M, Mogas T, Juanpere N, García F, Morote J, Nuñez F, Abal M, Lloreta J, Reventós J. A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model. Prostate 2010; 70:1402-12. [PMID: 20687213 DOI: 10.1002/pros.21175] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND Benign prostatic hyperplasia (BPH) represents the most frequent proliferative abnormality of the human prostate. In spite of the well-characterized architectural development of BPH, little is known about the cellular and molecular events that contribute to it. METHODS We have developed an animal model to evaluate the follow-up of hormone-induced BPH and the analysis of the gene expression associated with BPH. Immunohistochemistry on human patient samples validated the BPH-related molecular alterations. RESULTS Canine specific Affymetrix microarray analysis performed on sequential biopsies obtained from a beagle dog dynamic model characterized a number of genes altered during the onset of BPH. In addition to the genes involved in calcification, matrix remodeling, detoxification, cell movement, and mucosa protection (MGP, MMP2, TIMP2, ITIH3, GST, MT2A, SULT1A1, FKBP1B, MUC1, STRBP, TFF3), the up-regulation of TGFB3 and CLU indicated a complete adjustment of the transdifferentiation, senescence and apoptosis programs. The up-regulation of Clusterin was validated by RT-qPCR and immunohistochemistry, both in the dog dynamic model and in human samples, further confirming the suitability of the animal model for the study of the molecular alterations associated with BPH. CONCLUSIONS Transcriptome analysis performed on a dynamic animal model that accurately mimicked the human clinic, allowed us to characterize a gene expression pattern associated with the onset of BPH.
Collapse
Affiliation(s)
- F Gallardo-Arrieta
- Veterinary Faculty, Departament of Medicine and Animal Surgery, Autonomous University of Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|